Finasteride, a Selective 5-Alpha-Reductase Inhibitor, in the Prevention and Treatment of Human Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 4, 2004, Pages 206-208

  Reddy, G Kesava ^a   Sartor, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ANEMIA; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; GYNECOMASTIA; HUMAN; HYPOGONADISM; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCLE ATROPHY; OSTEOPOROSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION;

EID: 16544384425     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70045-2     Document Type: Article

References (15)

1. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52:213-235.
2. Lamharzi N, Johnson MM, Goodman G, et al. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int J Cancer 2003; 105:480-483.
3. Shibata A, Garcia MI, Cheng I, et al. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 2002; 52:269-278.
4. Soloway MS, Chodak G, Vogelzang NJ, et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group. Urology 1991; 37:46-51.
5. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33(suppl 5):45-52.
6. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford) 2002; 56:779-786.
7. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952-1956.
8. Kolvenbag GJ, Iversen P, Newling DW. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001; 58(suppl 1):16-23.
9. Trump DL, Waldstreicher JA, Kolvenbag G, et al. Androgen antagonists: potential role in prostate cancer prevention. Urology 2001; 57(4 suppl 1):64-67.
10. Rubin MA, Kantoff PW. Effect of finasteride on risk of prostate cancer: how little we really know. J Cell Biochem 2004; 91:478-482.
11. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
12. Picus J. The 5-alpha reductase enzyme in prostate cancer. Presented at: Third International Prostate Cancer Congress; July 17-20, 2003; Hamilton, Bermuda.
13. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995; 154:1642-1645.
14. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996; 78:907-910.
15. Ornstein DK, Rao GS, Johnson B, et al. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 48:901-905.